Disclaimer: Englemed is a news service and does not
provide health advice. Advice should be taken from a medical professional
or appropriate health professional about any course of treatment or therapy.

Anticoagulant drugs prevented 4,000 strokes in a year

An increase in the number of people with atrial fibrillation taking anticoagulant drugs helped
to prevent 4,000 strokes in England between 2015 and 2016, according to research published today.

Researchers at the University of Leeds, England, used national data and insight provided from
Imperial College Health Partners (ICHP) to analyse the known patients with AF, episodes of stroke,
new AF diagnoses and the use of anticoagulants amongst high risk patients between 2006 and 2016.

They found that, since 2009, the number of people with AF who are being treated with anticoagulants
has more than doubled, estimating that, had the uptake of anticoagulants stayed at 2009 levels,
there would have been about 4,000 more strokes in patients with AF in England in the 2015/16
financial year.

The research is published in the latest edition of the European Heart Journal.

It is believed that in the UK alone there are 500,000 people who have undiagnosed AF, a condition
that increases the risk of a stroke five-fold.

The British Heart Foundation, which part-funded the study, says the findings highlight the urgent
need for better screening and diagnosis of AF to ensure patients receive the clot-busting treatment
to help prevent a stroke.

Study co-author Chris Gale, professor of cardiovascular medicine and honorary consultant cardiologist
at the University of Leeds, said: “Sudden strokes in people who have AF are unnecessarily
common. Treatments which prevent AF-related strokes are saving lives, but there are still many
thousands of people in the UK living with undiagnosed AF who are missing out.

"The risk of AF rises dramatically with age. Our ageing population makes it clear that
without intervention, cases of AF and associated strokes are only going to increase. It’s
a truly preventable public health crisis.”

“The increased use of anticoagulants in patients with AF and the fall in the expected
number of strokes is a major success story – but much more needs to be done. There are
still half a million people in the UK with ‘silent’ AF, who have no idea they’re
at risk of having a stroke.”

* New anti-clotting drugs seem to be a safe alternative to warfarin, an observational study
has concluded.

Direct oral anticoagulants (DOACs), which are prescribed to treat serious blood clots, are associated
with reduced risks of major bleeding compared with warfarin, according to researchers at the
University of Nottingham, which investigated the risks and benefits of dabigatran, rivaroxaban,
and apixaban – the three most commonly used DOACs – compared with warfarin in patients
with and without atrial fibrillation.

They used data from two large UK primary care databases, identifying 196,061 patients who started
or restarted anticoagulants, after more than a 12-month gap, between 2011 and 2016.

Of these, 132,231 patients were taking warfarin, 7,744 dabigatran, 37,863 rivaroxaban, and 18,223
apixaban. A total of 53% (103,270) were diagnosed with AF, while the remaining 47% (92,791) were
prescribed anticoagulants for other conditions.

Patients were monitored for major bleeds leading to hospital admission or death, ischaemic stroke,
VTE, and all-cause mortality.

Writing in The BMJ, the research team says it found apixaban was associated with a lower risk
of major bleeding, particularly brain and gastric bleeds, in all patients, than the risk from
warfarin.

They also found a lower risk of brain bleeds associated with use of dabigatran in patients with
AF - and with use of rivaroxaban in patients without AF – than from warfarin.

However, rivaroxaban and low dose apixaban were associated with increased risks of deaths from
any cause in all patients when compared with warfarin. The researchers say this may reflect closer
monitoring of patients taking warfarin or may be related to other underlying conditions.

Although it is an observational study, the research team says its research shows that “the
risk of major bleeding is lower in apixaban users regardless of the reason for prescribing, appearing
to show apixaban to be the safest drug”.

They add: “Our results give an initial, reassuring, indication of the risk patterns for
all patients taking anticoagulants, in particular with respect to those prescribed apixaban.”